A 42-year-old man with X-linked chronic granulomatous disease (CGD) sought care at a hospital in Paris, France, for a 2-week history of cough and night sweats. He had been receiving long-term prophylaxis with itraconazole (400 mg/d) and had normal trough levels (1,240 μg/L) 1 month before his hospital visit.

At admission, blood counts showed mild leukocytosis (leukocytes 9.6 × 10^9^ cells/L, reference range 4--10 × 10^9^ cells/L), with neutrophils at 6.1 × 10^9^ cells/L (reference range 1.5--7 × 10^9^ cells/L) and eosinophils at 2 × 10^9^ cells/L (reference \<0.5 × 10^9^ cells/L). Computed tomography (CT) revealed an upper left lobe consolidation ([Appendix](#SD1){ref-type="local-data"} Figure). We administered broad-spectrum antimicrobial drugs (2 g meropenem 3×/d and 20 mg/kg/d amikacin). Results of bacterial and mycological cultures from sputum were negative, as was serum galactomannan.

The patient's condition did not improve, so we administered liposomal amphotericin B (5 mg/kg/d) and caspofungin (70 mg/d loading dose followed by 50 mg/d). Bronchoalveolar lavage demonstrated hypercellularity (1.22 × 10^6^ cells/mL); manual differential showed 12% macrophages and 76% eosinophils. Results of bacterial, mycological, and mycobacterial cultures were negative. Pathology studies from a transbronchial biopsy revealed numerous eosinophilic granulomas alongside Charcot-Leyden crystals ([Appendix](#SD1){ref-type="local-data"} Figure). Grocott methenamine silver staining revealed rare septated filamentous hyphae, but results of mycological cultures were negative. The patient had elevated total serum IgE (1,210 IU/mL, reference \<114 IU/mL), elevated serum *A. fumigatus* IgE (7 IU/mL, reference \<0.1 IU/mL) and *A. fumigatus* IgG (54 IU/mL, reference \<5 IU/mL), and precipitating antibodies to *A. fumigatus* (2 arcs of precipitation in immunoelectrophoresis). Results of parasitologic examination of fecal samples and serologic testing for alternative causes of eosinophilia were negative.

Eosinophilia persisted (1.8--2 × 10^9^ cells/L) despite antiparasitic treatment with ivermectin (5 mg/kg/d at days 1 and 7) and albendazole (400 mg/d for 7 d). Pathology findings from a transthoracic percutaneous biopsy revealed granulomas with Grocott-positive septated hyphae. Result of an *Aspergillus* section Fumigati PCR on a biopsy specimen were positive, and mycological cultures yielded a mold morphologically identified as *Aspergillus*. After 5 weeks of liposomal amphotericin B therapy (including 2 weeks of combination therapy with caspofungin), we switched treatment to oral voriconazole (loading dose of 400 mg 2×/d, followed by 200 mg 2×/d). Normalization of eosinophilia occurred at 6 weeks.

We sent mycological cultures from the biopsy specimens to the French National Center for Invasive Mycoses and Antifungals (Paris). Molecular identification based on the partial sequence of the internal transcribed spacer 2, 5.8S ribosomal RNA gene, and internal transcribed spacer 2 (525/526 bp; 99% similarity to the type strain, CBS 130245; GenBank accession no. KF558318.1) and the β-tubulin target gene enabled the identification of *Aspergillus felis* (109/109 bp; 100% similarity to the type strain, CBS DTO_131-E3 β-tubulin \[*benA*\] gene, partial cds; GenBank accession no. KY808576.1). The European Committee for Antimicrobial Susceptibility Testing (EUCAST) MICs with broth microdilution methods ([@R1]) were 4 μg/L for voriconazole, 4 μg/L for itraconazole, 0.25 μg/L for posaconazole, 2 μg/L for caspofungin, and 4 μg/L for amphotericin B. Based on EUCAST MIC breakpoints for *A. fumigatus* ([@R2]), we switched treatment to oral posaconazole (loading dose of 300 mg 2×/d, followed by 300 mg/d). Chest CT performed 12 months after treatment initiation showed noticeable improvement of pulmonary lesions.

Invasive pulmonary aspergillosis (IPA) remains a leading cause of death during CGD and IPA typically manifests as subacute pneumonia, with little or no angioinvasion ([@R3]). This patient had pulmonary infection caused by *A. felis* with overlapping features of IPA and allergic bronchopulmonary aspergillosis (ABPA) ([@R4]). Sensitization to *Aspergillus* spp. in patients with CGD ([@R5]) and tissue eosinophilia in lung pathology studies during invasive fungal infections ([@R6]) have been reported but do not seem to be common features of IPA in patients with CGD ([@R3],[@R7]). There was some uncertainty about whether *A. felis* was responsible for this overlapping phenotype between IPA and ABPA ([Table](#T1){ref-type="table"}).

###### Defining features of invasive pulmonary aspergillosis and allergic bronchopulmonary aspergillosis in a 42-year-old man with X-linked chronic granulomatous disease, Paris, France\*

  Category                                                     Defining features                                                                                                                                                
  ------------------------------------------------------------ ---------------------------------------------------------------- ---------------------------------------------------------- ------------------------------------ ------------------------------------------------------------
  Underlying disease                                           Neutropenia                                                      CGD, particularly X-linked CGD                             X-linked CGD                         Asthma, cystic fibrosis
  Mechanisms of disease                                        Angioinvasion                                                    Tissue invasion, little or no angioinvasion                No angioinvasion                     Exaggerated inflammatory response to *Aspergillus*
  Course of infection                                          Acute, single event                                              Subacute or chronic, single event                          Subacute, single event               Chronic with exacerbations
  Radiographic findings                                        Cavitation, pulmonary infarction, air crescent sign, halo sign   Single or multiple nodules and consolidations              Single consolidation                 Central bronchiectasis, pulmonary infiltrates, mucus plugs
  Galactomannan testing                                        Positive                                                         Positive or negative                                       Negative                             Negative
  Total serum IgE                                              Normal                                                           Normal                                                     Elevated (1,410 IU/L)                Elevated (\>1,000 IU/L)
  *Aspergillus* species-specific IgE or skin test reactivity   Negative                                                         Negative                                                   Positive (7 IU/mL)                   Positive (\>0.1 IU/mL)
  *Aspergillus* IgG                                            Negative                                                         Negative                                                   Positive (54 IU/mL)                  Positive (\>10 IU/mL)
  Precipitating antibodies to *Aspergillus*                    Negative                                                         Negative                                                   Positive (2 arcs of precipitation)   Positive (\>1 arc of precipitation)
  Blood eosinophilia                                           Absent                                                           Absent; reported only during "fulminant mulch pneumonia"   Present  (2.2 × 10^9^ cells/L)       Present  (\>0.5 × 10^9^ cells/L)
  First-line treatment                                         Antifungal treatment                                             Antifungal treatment                                       Antifungal treatment                 Systemic or inhaled corticosteroids

\*ABPA, allergic bronchopulmonary aspergillosis; CGD, chronic granulomatous disease; IPA, invasive pulmonary aspergillosis.

*A. felis* is a member of the *A. viridinutans* complex, a group of cryptic species belonging to *Aspergillus* section Fumigati ([@R8]). Such fumigati-mimetic molds are increasingly being recognized as sporadic causes of IPA ([@R9]). *A. felis* has been reported as a cause of sino-orbital aspergillosis in cats, but less frequently in humans ([@R8]). In one such case of IPA, and in the few reported cases in patients with CGD of IPA caused by the closely related *A. pseudoviridinutans* and *A. udagawae*, the course of infection was more protracted than for *A. fumigatus* infections, and dissemination occurred in a contiguous manner ([@R10]). Nonfumigatus *Aspergillus* spp. exhibit decreased in vitro susceptibility to commonly used antifungal drugs. Most previously reported antifungal susceptibilities from *A. felis* isolates showed high MICs for voriconazole and itraconazole but lower MICs for posaconazole ([@R8]).

Because isolates may be misidentified as *A. fumigatus*, culture-based morphological identification of invasive fungal infections in CGD may sometimes be insufficient. In cases of breakthrough fungal infections, or when faced with an atypical or refractory course of infection, identification of the fungus at a species level by molecular methods appears to be critical to guiding proper patient management.

###### Appendix

Images obtained from patient with chronic granulomatous disease who had *Aspergillus felis* infection.
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